



March 2, 2023

Liz Kwo, MD
Chief Medical Officer
Everlywell, Inc.
823 Congress Avenue
Austin, TX 78701

Device: Everlywell COVID-19 Test Home Collection Kit DTC
EUA Number: EUA203174
Company: Everlywell, Inc.
Indication: A direct to consumer product for collection of anterior nasal swab specimens at home from individuals age 18 years or older (self-collected), that are sent for testing with an in vitro diagnostic (IVD) molecular test that is indicated for use with the Everlywell COVID-19 Test Home Collection Kit DTC, and the IVD is indicated for testing any individuals, including individuals without symptoms or other reasons to suspect COVID-19.
Authorized Laboratories: Testing is limited to laboratories designated by Everlywell, Inc. that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet the requirements to perform high complexity tests.

Dear Dr. Kwo:

On February 13, 2021, based on your¹ request, the Food and Drug Administration (FDA) issued a letter authorizing the emergency use of the Everlywell COVID-19 Test Home Collection Kit DTC, as a direct to consumer product for self-collecting anterior nasal swab (nasal) specimen at home by any individual 18 years and older that are sent for testing with an in vitro diagnostic (IVD) molecular test that is indicated for use with the Everlywell COVID-19 Test Home Collection Kit DTC, and the IVD is indicated for testing any individuals, including individuals without symptoms or other reasons to suspect COVID-19, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). Testing was limited to laboratories designated by Everlywell, Inc., that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263, and meet the requirements to perform high-complexity tests. Based on your request, FDA reissued the letter on July 1, 2021.²

¹ For ease of reference, this letter will use the term “you” and related terms to refer to Everlywell, Inc.

² On July 1, 2021, the revisions to the February 13, 2021, letter and authorized labeling included: (1) updates to the intended use to expand collection of anterior nasal (nasal) swab specimens at home to individuals age 18 years and older (self-collected), 16 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance), (2) updates to the EUA Summary to include results of an updated sample stability and

On March 15, 2022, FDA received a request from you to amend your EUA. In response to this request, and having concluded that revising the July 1, 2021, EUA is appropriate to protect public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the July 1, 2021, letter in its entirety with the revisions incorporated.³ Pursuant to section 564 of the Act, Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product⁴ is now intended for the indication described above.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared on March 24, 2020, that circumstances exist justifying the authorization of emergency use of medical devices during the COVID-19 outbreak, subject to the terms of any authorization issued under that section.⁵

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is contained in the EUA Summary (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;

updated human usability studies including a study in minors, (3) updates to the Fact Sheet for Individuals and the instructions for anterior nasal swab collection to reflect the revised intended use and/or language used in more recent letters of authorization, and (4) update Condition Q below as a result of the new intended use.

³ The revisions to the July 1, 2021, letter and authorized labeling include: (1) removal of the “under 18” population claim from the intended use, (2) removal of Condition of Authorization Q (from the July 1, 2021, letter) which was both fulfilled and is no longer applicable with the removal of the “under 18” intended use population, (3) labeling modifications to mitigate the high rejection rate observed for the kit, and (4) add new suppliers of saline tubes used with the kit.

⁴ For ease of reference, this letter will use the term “your product” to refer to the Everlywell COVID-19 Test Home Collection Kit DTC used for the indication identified above.

⁵ U.S. Department of Health and Human Services, *Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. 85 FR 17335 (March 27, 2020)

2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, by serving as an appropriate means to collect and transport human specimens so that an authorized laboratory can detect SARS-CoV-2 RNA from the home-collected human specimen, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and
3. There is no adequate, approved, and available alternative to the emergency use of your product.⁶

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

Authorized Product Details

Your product is a direct to consumer product for collection of anterior nasal swab specimens at home from individuals age 18 years or older (self-collected), that are sent for testing with an in vitro diagnostic (IVD) molecular test that is indicated for use with your product, and the IVD is indicated for testing any individuals, including individuals without symptoms or other reasons to suspect COVID-19. Testing is limited to laboratories designated by Everlywell, Inc. that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet the requirements to perform high complexity tests.

When using your product, individuals must follow all specimen collection and mailing instructions provided with the kit. The Everlywell COVID-19 Test Home Collection Kit DTC includes the following materials or other authorized materials: poly mailer, 2D barcode label, anterior nasal swab, transport medium kit, kit ID stickers, return box, UN3373 label, medium alcohol prep pad, absorbent sheet, small biohazard bag, inner box tray, help and contact number insert, shipping and preparation instructions, collection instructions, Fact Sheet for Individuals, welcome panel with kit ID, white tray, and return shipping label.

All test results are delivered to the user via Everlywell's online portal. Individuals with positive or invalid/indeterminate results will be contacted by a healthcare provider.⁷ The direct to consumer home collection system is intended to enable users to access information about their COVID-19 infection status that could aid with determining if isolation or quarantine is appropriate and to assist with healthcare decisions after discussion with a healthcare provider.

The Everlywell COVID-19 Test Home Collection Kit DTC is not a substitute for visits to a healthcare provider. The information provided by this kit when combined with an authorized test should not be used to start, stop, or change any course of treatment unless advised by your healthcare provider.

⁶ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

⁷ For this EUA, a healthcare provider includes any health professional with prescribing abilities, including, but is not limited to, physicians, nurses, pharmacists, technologists, laboratory directors, and epidemiologists.

The labeling entitled “COVID-19 Test Home Collection Kit DTC Instructions,” “Everlywell COVID-19 Test Home Collection Kit DTC” box label, the EUA Summary (available at <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>), the following standard operating procedures (SOPs): “Receiving and Processing Everlywell Samples,” and the following fact sheet pertaining to the emergency use, is required to be made available as set forth in the Conditions of Authorization (Section IV), and are collectively referred to as “authorized labeling”:

- Fact Sheet for Individuals: Everlywell, Inc. - Everlywell COVID-19 Test Home Collection Kit DTC

The above described product, when accompanied by the authorized labeling provided as set forth in the Conditions of Authorization (Section IV), is authorized to be distributed and used under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

III. Waiver of Certain Requirements

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of your product, but excluding Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I

(Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

IV. Conditions of Authorization

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

Everlywell, Inc. (You) and Authorized Distributor(s)⁸

- A. Your product must comply with the following labeling requirements pursuant to FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).
- B. You and authorized distributor(s) must make available all instructions related to the self-collection of anterior nasal swab specimens using the Everlywell COVID-19 Test Home Collection Kit DTC and the Fact Sheet for Individuals both in the shipped kit and on your website(s).
- C. You and authorized distributor(s) must inform authorized laboratories and relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product, or the authorized labeling.
- D. Through a process of inventory control, you and authorized distributor(s) must maintain records of the numbers and locations to which your product is distributed.
- E. You and authorized distributor(s) must maintain customer complaint files on record. You will report to FDA any significant complaints about usability or deviations from the established performance characteristics of the product of which you become aware.
- F. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

Everlywell, Inc. (You)

- G. You must notify FDA of any authorized distributor(s) of your product, including the name, address, and phone number of any authorized distributor(s).

⁸ “Authorized Distributor(s)” are identified by you, Everlywell, Inc., in your EUA submission as an entity allowed to distribute the Everlywell COVID-19 Test Home Collection Kit DTC.

- H. You must notify FDA of any authorized laboratories designated by Everlywell, Inc. to use your product, including the name, address, and phone number of any authorized laboratories.
- I. You must provide authorized distributor(s) and authorized laboratories with a copy of this EUA and communicate any subsequent amendments that might be made to this EUA and its authorized labeling.
- J. You must ensure that the authorized laboratories using your product have a process in place for reporting test results to you, individuals, healthcare providers and relevant public health authorities, as appropriate.
- K. You must maintain records of the authorized laboratories and test usage.
- L. You must collect information on the performance of your product. You must report to FDA any suspected occurrence of false positive and false negative results and significant deviations from the established performance characteristics of your product of which you become aware.
- M. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation.
- N. You must comply with the following requirements pursuant to FDA regulations: 21 CFR 820 Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).
- O. You must have lot release procedures and the lot release procedures, including the study design and statistical power, must ensure that your product released for distribution has the clinical and analytical performance claimed in the authorized labeling.
- P. If requested by FDA, you must submit lot release procedures to FDA, including sampling protocols, testing protocols, and acceptance criteria, that you use to release lots of your product for distribution in the U.S. If such lot release procedures are requested by FDA, you must provide it within 48 hours of the request.
- Q. You must have a process in place to track adverse events associated with the Everlywell COVID-19 Test Home Collection Kit DTC, including any occurrence of false results and report to FDA pursuant to 21 CFR Part 803. Serious adverse events, especially unexpected biosafety concerns, must immediately be reported to DMD/OHT7/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov).

- R. You must have a process in place for reporting all test results to individuals who use the Everlywell COVID-19 Test Home Collection Kit DTC. This process must include a requirement that all positive and invalid/indeterminate results must be reported to individuals who self-collected specimens using the Everlywell COVID-19 Test Home Collection Kit DTC by a HCP, defined in footnote 6. This process must ensure the Fact Sheet for Individuals for the authorized IVD molecular test used on the specimen is made available to individuals with the test result, for example via weblink.
- S. You must have a healthcare provider available to provide information and counseling to individuals use the Everlywell COVID-19 Test Home Collection Kit DTC. You will ensure these healthcare providers have the Fact Sheet for Healthcare Providers that is relevant to the authorized IVD molecular test used on the specimen, for reference.

Authorized Laboratories

- T. Authorized laboratories using your product will use it only in conjunction with COVID-19 IVD molecular tests that are indicated for use with the Everlywell COVID-19 Test Home Collection Kit DTC.
- U. Authorized laboratories testing specimens self-collected using your product must follow the “Receiving and Processing Everlywell Samples” specimen accessioning protocol provided with your product when accepting specimens for testing.
- V. Authorized laboratories using your product must have a process in place for reporting test results to relevant public health authorities, as appropriate. Authorized laboratories using your product must also have a process in place for reporting test results to you via the agreed upon process, as described in the EUA Summary, for your product.
- W. Authorized laboratories must collect information on the performance of your product and report to DMD/OHT7/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and you (via email: covidsupport@everlywell.com or 512-309-5588) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the test of which they become aware.

Everlywell, Inc. (You), Authorized Distributor(s) and Authorized Laboratories

- X. You, authorized distributor(s) and authorized laboratories using your product must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

Conditions Related to Printed Materials, Advertising and Promotion

- Y. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and meet the requirements set forth in section 502(a), (q)(1), and (r) of the Act, as applicable, and FDA implementing regulations.

Z. No descriptive printed matter, advertising, and promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.

AA. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall clearly and conspicuously state that:

- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA;
- This product has been authorized only for the home collection and maintenance of anterior nasal swab specimens as an aid in detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of medical devices under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

V. Duration of Authorization

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of medical devices during the COVID-19 outbreak is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

Jeffrey E. Shuren, M.D., J.D.
Director
Center for Devices and Radiological Health
Food and Drug Administration

Enclosure